Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T50461
(Former ID: TTDI01632)
|
|||||
| Target Name |
Ribonuclease (RNase)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Cervical cancer [ICD-11: 2C77] | |||||
| 2 | Lung cancer [ICD-11: 2C25] | |||||
| 3 | Human immunodeficiency virus disease [ICD-11: 1C60-1C62] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | NTO-1151 | Drug Info | Phase 2 | Cervical cancer | [2] | |
| 2 | Ranpirnase | Drug Info | Phase 2 | Lung cancer | [3] | |
| 3 | MazF gene therapy | Drug Info | Phase 1 | Human immunodeficiency virus-1 infection | [4] | |
| Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
| 1 | AS-1406 | Drug Info | Terminated | Solid tumour/cancer | [5] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Modulator | [+] 4 Modulator drugs | + | ||||
| 1 | NTO-1151 | Drug Info | [1] | |||
| 2 | Ranpirnase | Drug Info | [6] | |||
| 3 | MazF gene therapy | Drug Info | [7] | |||
| 4 | AS-1406 | Drug Info | [8] | |||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Nanotherapeutics. | |||||
| REF 2 | Clinical pipeline report, company report or official report of Nanotherapeutics. | |||||
| REF 3 | ClinicalTrials.gov (NCT01184287) A Study Of Ranpirnase(Onconase) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer. U.S. National Institutes of Health. | |||||
| REF 4 | Clinical pipeline report, company report or official report of Takara Bio. | |||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012949) | |||||
| REF 6 | Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.Expert Opin Biol Ther. 2008 Jun;8(6):813-27. | |||||
| REF 7 | Clinical pipeline report, company report or official report of Takara Bio. | |||||
| REF 8 | WO patent application no. 2005,0657,17, Liquid formulations of antibody conjugates. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.